An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Pear Therapeutics to Participate in Evercore ISI Fourth Annual HealthCONx Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Pear Therapeutics, a leader in prescription digital therapeutics, will participate in the Evercore ISI Fourth Annual HealthCONx Conference on December 1, 2021. CEO Corey McCann will engage in a virtual fireside chat at 8:50 a.m. ET. A live audio webcast will be accessible through their website, with a replay available for 30 days after the event. Pear's innovative PDTs aim to enhance patient outcomes and offer effective solutions across various therapeutic areas, including FDA-approved treatments for substance use and insomnia.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the Evercore ISI Fourth Annual HealthCONx Conference on Wednesday, December 1, 2021. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 8:50 a.m. ET.
A live audio webcast can be accessed by clicking here and will be made available on Pear’s website at www.peartherapeutics.com. A replay will be available for approximately 30 days following the live presentation.
About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.
